PL EN


Preferences help
enabled [disable] Abstract
Number of results
2015 | 62 | 1 | 63-67
Article title

Assessment of the frequency of the transforming growth factor beta-1 sequence polymorphisms in patients with alcohol dependence syndrome

Content
Title variants
Languages of publication
EN
Abstracts
EN
Alcohol abuse is one of the most significant factors in the development of liver fibrosis. The pathomechanism of liver fibrosis is the same regardless of its etiology. Fibrosis is a sign of an imbalance between the synthesis of the extracellular matrix components and their degradation. Among the many cytokines that affect hepatic stellate cell activation it seems that transforming growth factor beta (TGF-β) is the most significant, either as the direct factor stimulating polymerase chain reaction (HSC) proliferation and transformation into myofibroblasts, or as the direct factor causing an increase in the activity of genes responsible for the synthesis of extracellular matrix components. The aim of the study was to reveal possible dependencies and differences between the presence of certain alleles of the TGF-β1 gene and its blood level in the study and control group. Blood samples were obtained from 39 patients, the control group consisted of 21 patients. The results obtained in the course of this study showed no statistically significant differences between the frequencies of particular polymorphisms. In the case of haplotype frequencies, insignificant differences were found for the algorithm Excoffier-Laval-Balding predicted haplotypes while one significant difference between the study and control groups was detected in case of the TC haplotype frequency predicted using the Expectation-Maximization algorithm. However, the difference in frequency of TC haplotype predicted by both algorithms was not significant. Genetic analysis of two single nucleotide polymorphisms (SNPs) in exon I of the TGF-β1 gene did not show significant differences between the occurrence of particular polymorphisms and haplotypes in the populations under study.
Publisher

Year
Volume
62
Issue
1
Pages
63-67
Physical description
Dates
published
2015
received
2014-04-27
revised
2014-12-09
accepted
2015-01-09
online
2015-02-24
Contributors
  • Chair and Department of Biochemistry, Nicolaus Copernicus University, L. Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
  • Chair and Clinic of Psychiatry, Nicolaus Copernicus University, L. Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
  • Department of Molecular Genetics and Court, Nicolaus Copernicus University, L. Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
  • Department of Molecular Genetics and Court, Nicolaus Copernicus University, L. Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
  • Department of Molecular Genetics and Court, Nicolaus Copernicus University, L. Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
  • Department of Medical Biology, Nicolaus Copernicus University, L. Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
  • Chair and Department of Biochemistry, Nicolaus Copernicus University, L. Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
References
  • Amani D, Zolghadri J, Dehaghani AS, Pezeshki AM, Ghaderi A (2004) The promoter region (-800, -509) polymorphisms of transforming growth factor-beta1 (TGF-beta1) gene and recurrent spontaneous abortion. J Reprod Immunol 62: 159-166.
  • Arias IM (1994) The liver biology and pathology. Raven Press, New York.
  • Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115: 209-218.
  • Berg T, Sarrazin C, Hinrichsen H (2004) Does noninvasive staging of fibrosis challenge liver biopsy as gold standard in chronic hepatis C? Hepatology 39: 1456-1457.
  • Chen WX, Li YM, Yu CH, Cai WM, Zheng M, Chen F (2002) Quantitative analysis of transforming growth factor beta 1 mRNA in patients with alcoholic liver disease. World J Gastroenterol 8: 379-381.
  • Flisiak R, Wiercińska-Drapało A, Tynecka E (2000) Transforming growth factor beta in the pathogenesis of liver diseases. Wiad Lek 53(9-10): 530-537 (in Polish).
  • Forns X, Ampurdanes S, Llovet JM (2002) Identification of chronic hepatitis C patients without fibrosis by a sipmle predictive model. Hepatology 36: 986-92.
  • Iredale JP (2003) Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 327: 143-147.
  • Katz GG, Shear NH, Malkiewicz IM (2001) Signaling for ethanol-induced apoptosis and repair in vitro. Clin Biochem 34: 219-227.
  • Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH (2005) Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 43: 78-84.
  • Kim YJ, Lee HS, Im JP, Min BH, Kim HD, Jeong JB, Yoon JH, Kim CY, Kim MS, Kim JY, Jung JH, Kim LH, Park BL, Shin HD (2003) Association of transforming growth factor-beta1gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp Mol Med 35: 196-202.
  • Kmieć Z (2003) The role of stellate cells in the regulation of liver function. Post Biol Komórki 30: 61-74 (in Polish).
  • Kozłowska J (2000) Liver fibrosis - attempts to treat. Terapia 8: 7-21 (in Polish).
  • Kozłowska J (2000) The pathogenesis of liver fibrosis. Pol Arch Med Wewn 104(3): 603-609 (in Polish).
  • Kozłowska J, Łoch T, Jabłońska J, Cianciara J (2001) Biochemical markers of fibrosis in chronic hepatitis and cirrhosis of viral etiology. Przegl Epidemiol 55: 451-458 (in Polish).
  • Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, Poynard (2004) The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatics C. Hepatology 39: 862-63.
  • Lebensztejn DM (2003) Current views on the pathogenesis of liver fibrosis. Pol Merkuriusz Lek 14: 174-176 (in Polish).
  • von Linsingen R, Bompeixe EP, Bicalho Mda G (2005) A case-control study in IL6 and TGFB1 gene polymorphisms and recurrent spontaneous abortion in southern Brazilian patients. Am J Reprod Immunol 53: 94-99.
  • Mazur W, Gonciarz M, Gonciarz Z (2003) Liver fibrosis - clinical aspects. Med Dypl 12: 30-39 (in Polish).
  • Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, Yano K, Nagaoka S, Matsumoto T, Nakao K, Hamasaki K, Yatsuhashi H, Ishibashi H, Eguchi K (2005) Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection- association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol 42: 505-510.
  • Myers RP, Tainturier MH, Ratziu V (2003) Prediction of liver histological lesions with biochemical markers in patients witch chronic hepations B. J Hepatol 39: 222-30.
  • Ogata Y, Enghild JJ, Nagase H (1992) Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267: 3581-3584.
  • Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM (2004) Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatics C patients. J Hepatol 41: 935-42.
  • Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J (2003) Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 38: 481-92.
  • Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704-13.
  • Rosenberg WM (2003) Rating fibrosis progression in chronic liver diseases. J Hepatol 38: 357-60.
  • Schuppan D, Afdhal NH (2008) Liver Cirrhosis. Lancet 371: 838-851.
  • Shah R, Rahaman B, Hurley CK, Posch PE (2006) Allelic diversity in the TGFB1 regulatory region: characterization of novel functional single nucleotide polymorphisms. Hum Genet 119: 61-74.
  • Shek FW, Benyon RC (2004) How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol 16: 123-126.
  • Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516.
  • Tamizifar B, Lankarani KB, Naeimi S, Rismankar M, Zadeh A, Taghavi A, Ghaderi A (2008) Promoter polymorphism of transforming growth factor-β1gene and ulcerative colitis World J Gastroenterol 14: 243-247.
  • Wick HD (1999) Alcohol problems in general practice - the value of biological markers. Praxis (Bern) 88: 1711-1714 .
  • Williams R (2006) Global challenges in liver disease. Hepatology 44: 521-526.
  • Wu J, Zern MA (2000) Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 35: 665-672.
  • Yong-Ku K, Boung Chul Lee, Byung Joo Ham, Byung-Hwan Yang, Sungwon Roh, Joonho Choi, Tae-Cheon Kang, Young-Gyu Chai, Ihn-Geun Choi (2009) Increased transforming growth factor-beta1 in alcohol dependence. J Korean Med Sci 24: 941-944.
  • Zafrani ES (2004) Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch 444: 3-12.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv62p63kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.